The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis

Who May Qualify: - Established diagnosis of UC according to the current European Crohn's and Colitis Organization (ECCO) guidelines7; - Age ≥ 18 years-old; - Capability of expressing willing to sign a consent form; - Clinically active ulcerative colitis (cf. 'operative clinical measures', below) at baseline; - Initiation of vedolizumab, ustekinumab or JAK inhibitors (tofacitinib, upadacitinib or filgotinib) as second-line target therapy at baseline; - Previous treatment with at least one anti-TNFα drug licenced for the treatment of UC (i.e., infliximab, adalimumab and/or golimumab); - No exposure to vedolizumab, ustekinumab and JAK inhibitors before baseline; - At least 1 follow-up visit after baseline Who Should NOT Join This Trial: - Diagnosis of Crohn's colitis, IBD-U or other gastrointestinal inflammatory conditions; - Age \< 18 years-old; - Incapability of expressing willing to sign a consent form; - Acute severe UC requiring hospitalization at baseline; - No previous exposure to anti-TNFα therapies; - Previous treatment with target therapies other than anti-TNF-α for UC before baseline; - Ustekinumab or JAK inhibitors induction with a non-standard posology for UC. Always talk to your doctor about whether this trial is right for you.